Apollomics, Inc. (NASDAQ:APLM) Sees Significant Decrease in Short Interest

Apollomics, Inc. (NASDAQ:APLM) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 2,600 shares, a decrease of 58.1% from the February 28th total of 6,200 shares. Based on an average trading volume of 17,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.3% of the shares of the company are sold short.

Apollomics Stock Down 10.3 %

APLM stock opened at $8.16 on Thursday. Apollomics has a 12 month low of $6.20 and a 12 month high of $75.00. The firm’s fifty day simple moving average is $8.01 and its 200-day simple moving average is $10.43.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.